New article in B2Africa, No. 2, September 2012:
"ViroGates - Measuring blood in the health care sector in Kenya"
See article here: 20120913 ViroGates in Africa
Read the article from Opfinderrådgivningen, Tekonologisk Institut, of the story behind suPARnostic® and the launch of the latest product, suPARnostic® Quick Triage:
"Dansk opfindelse kan fange sygdomssignaler i opløbet"
20120828 Ingeniøren article
ViroGates launches suPARnostic® Quick Triage product, receives product approval in Canada and enters into distribution agreement with Cedarlane
20120827 Press Release ViroGates: Product launch and Canada registration
20120827 Press Release ViroGates: Nyt produkt og registrering i Canada
See article in MedWatch August 8, 2012: 20120808 Medwatch article
"Dansk firma klar med værktøj til hurtig test af helbredsstatus"
See article in MedWatch August 24, 2012: 20120824 Medwatch article
"Medico-firma klar til markedsføring i USA og Canada"
ViroGates successfully completes new financing round and enters into a collaboration with NORCARE
20120104 Press Release ViroGates: New funding and collaboration
20120104 Pressemeddelelse ViroGates: Ny finansiering og samarbejdspartner
New article in Berlingske Nyhedsmagasin: "Medicovirksomhed jagter vækst i Afrika"
See article here: 20110824 VG in Berlingske Nyhedsmagasin
ViroGates has been granted a new patent to measure the risk of developing life style related diseases using its suPARnostic® biomarker product
20110822 Press Release ViroGates: New patent grant
20110822 Pressemeddelelse ViroGates: Nyt patent udstedt
ViroGates enters into agreement with Danish Cancer Research Foundation
20110510 Press Release ViroGates: License Agreement with Cancer Foundation.pdf
20110510 Press Release ViroGates: Ny licensaftale med Cancer Fonden.pdf
Jakob Knudsen appointed as new CEO at ViroGates
20110317 Press Release ViroGates New CEO.pdf (32.85 KB)
20110317 Press Release ViroGates Ny direktør.pdf (30.58 KB)
20110317 Picture Jakob Knudsen.jpg (193.33 KB)
ViroGates Changes Management Structure and Gears Up for Strong Sales Focus
20091014 Press Release ViroGates.pdf (13.11 KB)
Groundbreaking Results from Hospital Trial
20090917 Press Release ViroGates.pdf (338.61 KB)
ViroGates Extends Management Team and Hires New Head of Finance
20081117_Press Release ViroGates.pdf (272.67 KB)
ViroGates Launches 2nd. Generation suPARnostic® Product and Receives 2nd. Granted US Patent
20081117 Press Release ViroGates.pdf (271.90 KB)
ViroGates Fully Subscribes New Financing Round
20080604 Press Release ViroGates.pdf (261.98 KB)
ViroGates Enters Into a Long-Term Research Collaboration with Hvidovre Hospital
20080507 Press Release ViroGates.pdf (273.56 KB)
ViroGates Introduces Life-Saver
20080107 Press Release ViroGates.pdf (30.86 KB)
ViroGates Appoints Professor Knut Borch-Johnsen
The company announced today the appointment of Professor Knut Borch-Johnsen as Scientific Advisor.
ViroGates Changes Management and Board Structure
The biotech company today announced several changes in its management and board structure.
ViroGates Closes New Financing Round with Successful Exit for DTU Innovation/SEED Capital
The biotech company announced today that it has closed a private financing round of DKK 14.5 million.
ViroGates' HIV Monitoring Kit to be implemented in Denmark
ViroGates has entered into agreement with Hvidovre Hospital to supply the country’s largest HIV centre with its first-in-class HIV disease monitoring test.
ViroGates Receives CE Certification
ViroGates has received CE Mark certification for its first-in-class HIV patient monitoring assay - the suPARnostic™ kit is the company’s first product to achieve the CE Mark certification.
suPAR recognized as one of the most important Danish discoveries
The protein suPAR has been recognized by the Danish Patent and Trademark Office as one of the most important and life saving Danish inventions in life science.
suPARnostic™ introduced at the XVI World AIDS Conference in Toronto 2006.
ViroGates Oversubscribes 3 Times Its Latest Private Round
In its largest financing round to date, ViroGates raises new capital from both current and new investors.
ViroGates nominated as most promising company in Medicon Valley
Foreign investors will get their first glimpse of ViroGates, as the small biotech company has been selected to present its business case to both UK and US investors in June.
ViroGates Completes Development of First-In-Class HIV Prognostic Kit
After years of extensive research and development, ViroGates has completed production of the first batch of suPARnostic™ kits for the monitoring of HIV disease progression.